Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis

Abstract

A once-yearly infusion of zoledronic acid during a 3-year period significantly reduced the risk of vertebral, hip, and other fractures. (ClinicalTrials.gov number, NCT00049829.)